Cargando…
MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
MDM2 is the principal inhibitor of p53, and MDM2 inhibitors can disrupt the physical interaction between MDM2 and p53. The half-life of p53 is very short in normal cells and tissues, and an uncontrolled increase in p53 levels has potential harmful effects. It has been shown that p53 is frequently mu...
Autores principales: | Romani, Arianna, Zauli, Enrico, Zauli, Giorgio, AlMesfer, Saleh, Al-Swailem, Samar, Voltan, Rebecca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632280/ https://www.ncbi.nlm.nih.gov/pubmed/36338723 http://dx.doi.org/10.3389/fonc.2022.1000677 |
Ejemplares similares
-
Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation
por: Zauli, Giorgio, et al.
Publicado: (2022) -
State of the Art of Pharmacological Activators of p53 in Ocular Malignancies
por: Casciano, Fabio, et al.
Publicado: (2023) -
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
por: Tisato, Veronica, et al.
Publicado: (2017) -
Nutrients, herbal bioactive derivatives and commensal microbiota as tools to lower the risk of SARS-CoV-2 infection
por: Romani, Arianna, et al.
Publicado: (2023) -
Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
por: Rimondi, Erika, et al.
Publicado: (2021)